Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis

Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis is a phase 3, randomised interventional study registered as NCT06961188 by Changchun GeneScience Pharmaceutical Co., Ltd., with a registry enrolment figure of 174 participants, started 2025-06-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: Nano-crystalline Megestrol Acetate Oral Suspension; Standard Therapy. Conditions listed: Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity; Untreated With Systemic Therapy. Primary outcome: Proportion of appetite improvement assessed by A/CS-12 (Anorexia/Cachexia Subscale of Functional Assessment of Anorexia/Cachexia Therapy); Proportion of individuals with weight gain exceeding 5% relative to baseline. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed metastatic (stage IV) driver gene-negative non-squamous non-small cell lung cancer (NSCLC) that is unresectable and not amenable to curative therapy". Sites: China. No results are recorded here; the registry entry is the source.